Protocols
16 protocol(s) meet the specified criteria
Disease Site: Ovary
Protocol No.TitleStatus
A031102-CIRBA Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (Tip) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed By High-Dose Carboplatin And Etoposide (Ti-Ce) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Open
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaOpen
ASG-22CE-13-2A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4Open
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
GOG-0225Can Diet and Physical Activity Modulate Ovarian, fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?Open
GOG-0264A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary Open
GOG-3012A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD- Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyOpen
GOG212A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND # 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Acheive a Complete Clinical Response to Primary Platinum/Taxane ChemotherapyOpen (affiliates only)
INCAGN1876-201A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination with Immune therapies in Subjects with Advanced or Metastatic MalignanciesOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1734Adaptation of the Parenting Concerns Questionnaire for Patients with IllnessOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
MM-398-01-01-02A Phase 1 Study in Patients Treated with MM-398 (Nanoliposomal Irinotecan, nal-IRI,) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentOpen
MORAB-003-011A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian CancerOpen
NC-6300-001A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaOpen